Assessing Tarsus Pharmaceuticals after recent share price moves

Tarsus Pharmaceuticals (TARS) has seen its stock give back some ground recently, with shares down about 7% over the past month and roughly 22% over the past 3 months, prompting fresh questions from investors.

At a recent share price of $59.40, the stock has lost momentum in the short term, with weaker 1 week, 1 month and 3 month share price returns contrasting with a much stronger multi year total shareholder return profile. This reflects how investors have previously responded to Tarsus Pharmaceuticals' progress in eye care and infectious disease programs.

If you are weighing up Tarsus Pharmaceuticals against other potential opportunities in healthcare, it can be useful to see how the market is pricing 39 healthcare AI stocks

With Tarsus Pharmaceuticals trading at $59.40 and indications of a wide gap to some estimated values, the key question is simple: are you looking at an undervalued growth story, or has the market already priced in what comes next?

Most Popular Narrative: 37.5% Undervalued

With Tarsus Pharmaceuticals last closing at $59.40 against a narrative fair value of about $95.11, the current setup points to a wide valuation gap that hinges on execution in both eye care and infectious disease.

The company's pipeline expansion (e.g., TP-04 for ocular rosacea) positions Tarsus for multi-product leverage in underserved markets, supporting diversified, long-term earnings growth and reducing future revenue concentration risk. International growth opportunities, with regulatory efforts underway in Japan and the EU, set the stage for a larger global revenue base and potential margin lift as XDEMVY achieves broader adoption outside the U.S.

Curious what has to happen in eye care prescriptions, Lyme prevention and margins for that higher value to add up? The narrative leans on ambitious revenue expansion, a sharp swing into profitability and a richer future earnings multiple that is above the broader pharmaceuticals sector. Want to see how those moving parts combine into that fair value and how sensitive it is to even small changes in the assumptions?

Result: Fair Value of $95.11 (UNDERVALUED)

However, the story can change quickly if XDEMVY uptake disappoints or if high selling and marketing costs weigh on margins for longer than analysts expect.

Next Steps

If this mix of risks and rewards feels finely balanced, consider acting while the data is fresh and test the thesis yourself with the full 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop here, you risk missing other opportunities that fit your style, so take a few minutes to scan a broader set of stocks with solid fundamentals.

• Target rock solid balance sheets by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) to see which ones align with your risk comfort.
• Hunt for potential value candidates across the market using the 46 high quality undervalued stocks and see which stocks match your expectations.
• Spot early stage opportunities with financial filters doing the heavy lifting through the 23 elite penny stocks with strong financials before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.